Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSSpecial Articles
You have accessRestricted Access

Frontiers in Nephrology: The Evolving Therapeutic Applications of Endothelial Progenitor Cells

Jörn Tongers and Douglas W. Losordo
JASN November 2007, 18 (11) 2843-2852; DOI: https://doi.org/10.1681/ASN.2007050597
Jörn Tongers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas W. Losordo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Abstract

Cardiovascular-renal diseases are the leading causes of death and disability in the modern world. Moreover, chronic heart failure after myocardial infarction and peripheral arterial disease are predominant, devastating cardiovascular entities that limit prognosis and greatly impair quality of life in patients despite modern medical treatments. Cardiovascular diseases are also the predominant cause of death in people with renal diseases, underscoring the close relationship between these diseases. Until recently, medical efforts aimed only at prevention and slowing of functional deterioration after organ damage; however, the recent discovery of endogenous repair mechanisms involving hematopoietic stem and other progenitor cells has challenged the long-standing dogma regarding the inability to repair or regenerate terminally differentiated organs. A variety of stem and progenitor cell populations have shown properties that are potentially suited for tissue repair. After encouraging results in preclinical animal models, early clinical studies of endothelial progenitor cells (EPC) have begun. Envisioning the goal of true tissue regeneration, application of bone marrow–derived progenitors for heart and limb ischemia has provided early evidence of safety and feasibility. These studies have provided data indicating functional improvement as well. Although there is strong experimental and clinical evidence for a regenerative function of EPC even in renal disease, there has been no clinical application of this approach. After the initial flurry of activity, it is time to reconsider these approaches and attempt to optimize functional improvement and patient safety. This article briefly recapitulates biologic and functional characteristics of EPC before giving a concise overview on current therapeutic EPC applications in the field of cardiovascular-renal medicine with consideration of future challenges.

Cardiovascular-renal diseases constitute a growing epidemic in the Western world. Thus far, therapeutic approaches to treat these conditions have focused on merely preventing cellular damage and slowing the progression of functional deterioration. In light of the ever-increasing socioeconomic burden, modern medicine has been challenged to develop ways to regenerate damaged, dysfunctional organ tissue.

As a result of a fundamental shift in the underlying cause of chronic heart failure, long-term survival after myocardial infarction is now the most common cause of chronic heart failure.1 Given the incidence of coronary artery disease worldwide, postischemic chronic heart failure is a major cause of cardiovascular-renal morbidity and mortality. Enormous advances have occurred in disease understanding and treatment-attenuated progression, leading to improved quality of life and outcome. Still, the prognosis remains limited. Because of a limited capacity of cardiac tissue self-repair, death of cardiomyocytes has always been considered irreversible. Improvement or renewal of cardiac function in akinetic scar tissue, by replacement and reperfusion, would prove ideal in reversing this progressive cycle.

Peripheral arterial disease is a predominant entity in vasculature, causing intractable ischemia, impaired mobility, compromised wound healing, ulceration, and amputations.2 Furthermore, all-cause mortality is similar to coronary artery disease.3 Despite improved management of cardiovascular risk factors and advances in medical treatment, the disease course is often insidious.4 Angiogenic strategies designed to reperfuse ischemic limbs offer potential for relief of symptoms or even rescuing limbs.

Cardiovascular and renal diseases are closely related. Chronic kidney disease is another worldwide health problem associated with poor outcomes and high costs.5 In the United States, the prevalence of kidney failure doubled in the past decade. Patients with renal disease are burdened by exceptionally high cardiovascular morbidity and mortality.6,7 They predominantly die of arteriosclerotic diseases such as myocardial infarction and stroke.6

Within recent years, evolving research has challenged the classical dogma that terminally differentiated organs lack the capacity for cell turnover and regeneration. The recent discovery of endogenous repair mechanisms implicating hematopoietic stem and progenitor cells set off the concept of tissue repair. By definition, stem cells (SC) possess the capability of self-renewal, transformation into dedicated progenitor cells, and differentiation into specialized progeny such as endothelial progenitor cells (EPC).

Theoretically, a variety of SC and progenitor cell populations possess properties that are suited to tissue repair. Apart from EPC, mesenchymal, embryonal, resident cardiac, embryonic stem cells and skeletal myoblasts are considered, respectively. Each population brings its own profile of advantages, disadvantages, and, most important, practical limitations in the clinical setting. Because comparative evaluations of cell populations remain scarce, some investigators applied unfractionated bone marrow (BM) cells (BMC) containing various stem and progenitor populations, including hematopoietic SC and EPC. This review focuses on the regenerative potential of EPC. We briefly recapitulate the biologic characteristics and functional cascade of EPC from mobilization out of the BM to their migration and eventual functioning at the site of ischemia. We consider current therapeutic applications of EPC in the field of cardiovascular-renal medicine in regard to technical aspects and future challenges.

EPC

Cellular Biology

In contrast to SC, progenitor cells are immature cells with a more limited differentiation potential. They proliferate for a finite number of cell divisions.7–10 By convention, EPC are characterized by hematopoietic SC markers such as CD34 or CD133 and expression of an endothelial surface marker (vascular endothelial growth factor receptor-2 or kdr, von Willebrand factor, VE cadherin, CD146), uptake of Dil-acetylated lipoprotein, and lectin binding.11 On the basis of surface markers, EPC can be quantified and isolated by flow cytometry. Because of their adhesion properties to fibronectin, EPC can be further grown in culture from unfractionated BMC using selectively enriched medium.

EPC that were originally isolated from the mononuclear cell fraction of peripheral blood12 have subsequently also been isolated from human umbilical cord blood as well as from mononuclear cell, CD34+ and CD133+ hematopoietic SC fraction derived from BM. It seems that the BM may not be the single source of EPC, because a CD14+/CD34−/CD133− mononuclear side population with angiogenic profile has been characterized in various tissues.11 Overall, controversy still exists regarding the identification and origin of EPC.11

Mobilization and Homing of EPC

Whereas EPC levels remain low under normal conditions,12 ischemia of limb muscle or myocardium is believed to be the predominant trigger for EPC to travel from the BM niche. The release of EPC from BM is regulated by a variety of growth factors, enzymes, ligands, and surface markers. Today, the concept of EPC mobilization envisions an ischemia-dependent secretion of proangiogenic cytokines as stromal cell–derived factor-1 (SDF-1)13–15 or vascular endothelial growth factor (VEGF)16,17 induced by hypoxia-inducible factor at the site of ischemia, which, in turn, are released to the circulation.14 Other EPC-mobilizing factors are placental growth factor, G-CSF, and GM-CSF. In the BM, however, activation of matrix metalloproteinase-9, which cleaves membrane-bound Kit ligand to a soluble Kit ligand, releases cKit+ EPC to the vascular zone of the BM niche.18 Endothelial nitric oxide synthase–derived nitric oxide is a prerequisite for matrix metalloproteinase-9.19

Hetero-, homo-, and autologous EPC are capable of entering sites of active neovascularization. Asahara et al.17 detected donor-derived EPC in the myocardium after myocardial infarction. This observation provided the first support of the concept that ischemia-mobilized EPC invade ischemic tissue and participate in postnatal angiogenesis (homing). Recruitment of EPC requires a coordinated sequence of multistep adhesive and signaling events, including adhesion, chemoattraction, and migration. Integrins and tissue-specific adhesion molecules are key elements for adhesion of hematopoietic SC.20 Angiogenic chemokines such as SDF-1 and VEGF do not merely function systemically to mobilize EPC from the remote BM. These factors also attract circulating EPC locally to the ischemic tissue, as we and others have shown. SDF-1 overexpression enhances homing of EPC21 that are particularly sensitive to SDF-1.22 It is interesting that the migratory capacity of EPC toward SDF-1 and VEGF determines functional improvement of postinfarct patients.23

Regenerative Mechanisms

For a long time, researchers believed the vascular endothelium to be an inactive, inner lining of blood vessels. Repair of the endothelium was believed to occur by proliferation of endothelial cells from wound margin to center. However, in recent years, the endothelium has been identified as a highly active structure running from the endothelial layers of conduit vessels through into microcirculation. In addition to providing lining, the endothelium provides essential functions. Moreover, the disease process of “dysfunctional” endothelium is closely related to arteriosclerosis and cardiovascular disease.24,25 An even more novel perspective proposes an interaction of BMC and EPC with the endothelium to repair vasculature by angiogenic action.26 Shi et al.27 also observed a rapid coverage of implanted grafts by CD34+ BMC (engraftment).

Angiogenesis is crucial for preservation of tissue function in critical ischemia. This mechanism is driven by ischemia and represents growth of new capillaries by sprouting and intussusception from preexisting capillaries. The mechanism is clearly distinct from arteriogenesis, the collateral growth from conduit arteries driven by biomechanical forces. Asahara et al.12 first linked EPC to postnatal angiogenesis in their seminal study. EPC have further been shown to promote repair of endothelium (reendothelialization)28,29 and postnatal formation of new capillaries (neovascularization).12,17 This finding has been reinforced by animal models of hind-limb ischemia and myocardial infarction, where progenitor cells induced new vessel formation.30–33

Earlier, EPC were believed to affect vascular repair by differentiation into endothelial cells. At first, tracking of engrafted cells initially revealed the expression of cardiac and/or endothelial marker proteins pointing to a tissue-specific differentiation of transplanted cells.9,34,35 Subsequently, the observation of SC transdifferentiation was more accurately explained as cell–cell fusion of transplanted and local cells.36,37 Consistent with the idea of transdifferentiation, EPC historically were reported to incorporate vessel structure. In line with other investigators,38,39 Ziegelhoeffer et al.40 questioned the hypothesis, observing no incorporation of BMC into growing vessels structure while BMC accumulated in perivascular areas. Hence, the capability to promote vascular growth seemed to be related to paracrine effects.

Homing of EPC to the ischemic tissue releases cytokines, chemokines, and growth factors. These secreted factors, in turn, affect the surrounding ischemic tissue in a paracrine manner. BM-derived mononuclear cells have been reported to release multiple angiogenic cytokines such as VEGF, angiopoietins, and fibroblast growth factor.41–43 Angiogenic factors have originally been discovered in the regulation of tumor vascularization.44 EPC promote angiogenesis, suppress cell death of resident cells, and recruit SC by factor release.41,43,45 Because SC and progenitor cells might serve more as a “cytokine factory” rather than the building material,46 the external EPC application potentially boosts endogenous repair mechanisms after ischemia occurs. Therefore, cell therapy at this time seems more favorable than a single-gene therapy.47

Preclinical Experiences

Driven by a multitude of experimental findings that have elevated the role EPC in tissue repair, we and others have extensively studied EPC in animal models of ischemic hind-limb7,12,17,48–50 and myocardium.9,31,35,41,51–55 Of interest in our study, mononuclear cells that were depleted of CD34+ cells failed to improve myocardial function after infarction,9 suggesting that the CD34+ population plays an important role in regeneration by BMC transplant. Systemic application of expanded EPC31 and selective application of purified CD34+ cells9,31 or mononuclear BMC41 improved myocardial function. In another preclinical animal study,54 we also observed functional improvement in chronic myocardial ischemia. Although the underlying mechanisms require further definition, the regenerative characteristics of EPC provide a highly attractive therapeutic option.45

Clinical Implications of EPC

EPC and Cardiovascular Disease

EPC correlate well with risk factors of arteriosclerosis; age, smoking, hypercholesterolemia, and diabetes affect EPC number and function.56–60 Manifest coronary artery disease, angina pectoris, and myocardial infarction have a robust impact on EPC mobilization.33,61–66 In particular, unstable angina pectoris and acute myocardial infarction augment EPC levels.65,67 EPC levels are also inversely related to the severity of congestive heart failure.64,66 Conversely, physical activity enhances EPC levels and activity.68 Statins, an essential in gold-standard treatment of cardiovascular disease, revive EPC levels by activation of the Akt/phosphatidylinositol-3 kinase pathway.60,69 Other vasoprotective drugs, such as angiotensin receptor blockers, show similar effects.70 Overall, the biology of EPC is strongly related to the cardiovascular risk burden in healthy and manifest individuals.

EPC and Renal Disease

Comparatively little is known about EPC for renal disease treatment. Functional recovery after toxic or ischemic kidney mainly comes along with proliferation and replacement of tubular cells.71 Endothelial and tubular cells have a remarkable capacity to recover. Although the underlying mechanisms are not fully understood, replacement of damaged cells will mainly be generated by neighboring cells or cells recruited from the circulation. Although the origin of newly generated renal cells remains to be determined, it has been observed that BMC can repopulate nephrons after ischemia.72 Therefore, the role of progenitor cells in treating renal disease deserves greater attention.

In the clinical setting, renal diseases in concert with cardiovascular risk factors significantly influence the number and function of EPC. Advanced renal failure,73 dialysis,74,75 and renal transplantation impair EPC capacity.76 Adverse findings of elevated EPC in some studies might be explained by concurring drug therapy, for example, erythropoietin (EPO). Uremia has further been described to alter EPC function as to differentiation, mobilization, migration, and tube formation.73,76 In a previous study,77 fewer CD34+ and AC133+ cells were circulating in patients undergoing dialysis compared with a control group. More recently, Westerweel et al.78 found the balance between vasoprotective EPC and adverse smooth muscle progenitor cells adversely shifted to a state of impaired vascular repair in patients with end-stage renal disease. Similarly, chronic renal disease tends to impair EPC, even though it is barely possible to separate the potential effect from confounders.

Conversely, support or replacement of renal function seems to be accompanied by recovery of EPC biology.79 Within 12 mo after kidney transplantation, uremia-induced EPC function was restored in a small sample population, although EPC numbers remained unchanged.80 In line with this finding, already nocturnal hemodialysis improved impaired EPC levels and function in patients with end-stage renal disease, whereas in the conventional hemodialysis group, EPC biology was impaired. Speculatively speaking, this finding might be explained by a poorer uremic clearance from intermittent conventional dialysis.81 EPO, an important hematopoietic factor that is deficient in chronic renal disease, has also been shown to affect EPC. EPO plasma levels are independently related to EPC levels.82 In vivo studies showed that application of recombinant EPO, in turn, augments EPC levels in the spleen and peripheral blood by activating the Akt kinase pathway.83

Referring to their regenerative properties, EPC seem to support repairing mechanisms in kidneys of endothelial, mesangial, and tubular structures. Transplantation of EPC expanded from a muscle SC pool, locally engrafted, and improved renal function in an acute renal ischemia rat model.84 If the rate of glomerular cell renewal under normal conditions averages approximately 1% per day,85 the rate is accelerated after injury. Some animal studies provide evidence that EPC contribute to glomerular capillary repair.86,87 In humans, acceptor-derived EPC have been localized in kidney allografts, replacing donor endothelial cells and potentially repairing transplant-related vascular injury.88 In a glomerulonephritis rat model, injection of BM-derived mononuclear cells into the renal artery improved endothelial injury and mesangial cell activation.89 BM-derived progenitors are involved in the turnover and repair of mesangium72,90,91 and tubules, which are highly regenerable.92,93

Overall, these findings strongly advocate that EPC can also play a significant role in renal repair and present an exciting target for regeneration in renal disease.

Therapeutic Applications

Apart from ideal cell type, the route of cell delivery is another critical question. Basically, the goal of cell transplantation is to selectively deliver an optimal number of the most effective cells to the region of interest without safety concerns and via a minimally invasive route. It follows that cell retention, the fraction of cells that are retained in the transplant site over time, and local milieu, which determines cell fate, are relevant. In case of transvascular applications, even endothelial cell adhesion, vessel wall transmigration and tissue invasion are variables of transplant efficiency.

Routes of Delivery: Transvascular versus Direct Application

Taking the lead from selective coronary artery intervention, cell transplantation after myocardial infarction is delicately performed through a balloon-tipped catheter by small access. For optimization of the contact time of cells and coronary microcirculation, cell infusion will be performed while the inflated balloon blocks cell reflux.94 In addition, this transvascular cell therapy is influenced by the secretion of chemoattractive factors from the ischemic tissue after a recent infarction or in recurring ischemia.95 In contrast, even though intravenous infusion of EPC seemed to have some effect on cardiac function after infarction,96 un-selective tissue homing to nontarget organs limits efficiency using this approach.97 A comparative study of both approaches confirmed only cell homing after the transvascular method of infusion.98

In the case of chronic infarction, a transvascular strategy might be impaired by occlusion of the afferent artery. Abated chemoattraction after a previous infarction will further impede the transvascular approach. Direct cell injection into ischemic tissue overcomes these impairments and, therefore, seems the more suitable approach in the case of chronic infarction. With regard to the heart, direct injections have been performed transepicardially and transendocardially. On the downside, direct injection causes cell cluster in malperfused tissue, resulting in poor cell survival, whereas conceptually, transvascular cell transfer should distribute cells more homogeneously. Conversely, direct application allows for the delivery of larger cells such as myoblasts, which cannot be applied transvascularly by virtue of microembolization. Direct injection, which is even more invasive, because in terms of the heart it requires direct access, can also be considered. The more invasive the techniques, the higher are the periprocedural risks for patients who already have cardiovascular-renal disease. Last but not least, mechanical puncture of necrotic myocardium comes with an inevitable risk for perforation and ventricular rupture. This, however, is not true for leg ischemia.

Both SC and progenitor cells can be mobilized from their home in BM into the peripheral circulation using a cytokine. This noninvasive strategy is borrowed from hematologists who isolate SC before BM is irradiated for SC transplantation. The systemic applications of the potent cytokine SC-mobilizing agents SC factor and G-CSF also improved cardiac function after infarction in animals.35,99 Thus, it seems systemic application of mobilizing factors has the potential to augment EPC-mediated repair mechanisms safely and effectively.

Myocardial Disease

Myocardial Infarction

Soon after experimental data suggested a functional improvement in cardiac function by using cells from BM after infarction,31,37,54,55 human studies were done by infusing selected or unselected BMC into the artery that was blocked, in addition to traditional treatment. Initially, three smaller, uncontrolled studies94,100,101 suggested feasibility of intracoronary application of BMC in humans. Since those earlier attempts, a couple of larger, randomized, partly placebo-controlled trials have been completed. In the randomized, controlled Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) and Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration (BOOST) trials, global left ventricular (LV) function was improved 4 to 6 mo after cell transfer, although LV dimensions remained unchanged.102,103 These promising studies were opposed by two negative trials that had some relevant differences in study design, even though the exact reasons for the conflicting results remain elusive. For example, Janssens et al.104 infused BMC a full day after the infarction when acute coronary reperfusion had already occurred. In the other study, the Autologous Stem Cell Transplantation in Acute Myocardial Infarction (ASTAMI) trial, the baseline magnetic resonance imaging was not performed until 2 to 3 wk after the cell transfer. Cells were administered late and, of greater concern, prepared differently.105 However, both studies failed to show an improvement of LV function or dimension 4 and 6 mo, respectively, after cell transfer. In longer follow-up of REPAIR-AMI, the improvement of LV function remained stable after 12 mo,106 whereas the 6-mo effects were no longer present at 18 mo of follow-up of the BOOST collective.107 However, looking at the studies overall suggests that the infusion of BMC into the once blocked, recanalized artery is both safe and efficient. No adverse events, such as in-stent stenosis, stent thrombosis, ventricular arrhythmias, myocardial calcifications, or tumor formation were reported during the period from infusion to 18 mo afterward. Double-blind, large-scale, randomized, placebo-controlled, multicenter trials are under design to investigate further these promising results. The strategy to mobilize progenitor cells after myocardial infarction by administering G-CSF is highly debated. The much criticized Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF (MAGIC) pilot study revealed an increased risk for in-stent restenosis, apart from its problematic design.108 G-CSF–induced cell mobilization performed shortly after an acute angioplasty in acute infarct improved LV function and metabolic activity at the cost of serious adverse effects.109 Another study with a more favorable risk profile did not show a beneficial effect on LV function.110 All in all, we strongly believe that the safety of G-CSF application for cell mobilization in myocardial infarction must be studied further.

Intractable Coronary Artery Disease

Some patients with diffuse coronary artery disease and without any option of revascularization have intractable angina despite optimal medial treatment. Recurrent myocardial ischemia can further deteriorate already poor cardiac function by hibernation of viable myocardium. In this therapy-refractory, highly compromised population, cell therapy offers the single potential to relieve symptoms as well as improve quality of life by augmenting regional perfusion; there is nothing else to offer them. SC and progenitor cells seem to deliver a cocktail of angiogenic cytokines to ischemic tissue.46 In a set of small-scale studies, patients received direct injection of unfractionated BMC transepicardially, during open-heart surgery,111 or transendocardially, under electromechanical guidance.52,112,113 Overall, both approaches seemed safe and feasible. Pathology, physical capacity, and ventricular function were reported to improve. Small patient numbers and uncontrolled study designs, however, do not allow final conclusions regarding treatment efficacy. Therefore, larger, randomized, controlled studies are needed. It is interesting that the strategy of noninvasive pharmacologic mobilization of EPC by G-CSF did not improve myocardial function, while effectively increasing circulating EPC. In addition and of great concern, myocardial reinfarction associated to G-CSF therapy was reported.114 Because harvesting and infusing mobilized cells to chronically infarcted tissue remains uncertain, it cannot be promoted.

Chronic Heart Failure and Ischemic Cardiomyopathy

Encouraged by the results in its use for myocardial infarction, cell therapy was offered to patients with chronic heart failure after previous infarction. In the initial study, CD133+ cells were directly injected into the infarct boarder zone during a bypass procedure in patients who had had previous myocardial infarction. Because no adverse events were reported, treatment was considered safe and feasible. The finding of improved LV function is limited by the lack of a control group.115,116 In another study, unfractionated BMC were injected transvascularly. The follow-up did not reveal any safety concerns while significantly increasing LV function compared with the control groups.117 The most comprehensive study on this group was recently published by Assmus et al.118 In a carefully designed crossover study, the authors observed a significant improvement of ventricular function 3 mo after transvascular application of BM-derived progenitor cells in patients with resolved myocardial infarction.

Peripheral Arterial Disease

So far, only a single study has used cell therapy in peripheral vascular artery disease. In the randomized, placebo-controlled Therapeutic Angiogenesis using Cell Transplantation (TACT) study, symptoms and parameters of leg ischemia were alleviated after the injection of BMC by inducing neovascularization.119 Further studies are need to underscore this single-study finding.

Renal Disease

The complex structure of kidneys, with their arterioles, capillaries, glomeruli, and tubules interacting in a three-dimensional structure to provide the complex function of filtration and reabsorption, complicates regenerative approaches. Because renal tissue was believed to be terminally differentiated, regeneration once renal damage has occurred seemed to be impossible. Encouraged by promising experimental findings as described in the cardiovascular system, a clinical approach seems to be worth further study. To our knowledge, no investigation of cell therapy to promote kidney repair has been published but should come soon; however, referring to the implications of EPO and EPC, it is of particular interest that the application of recombinant EPO improved EPC levels and functions in a pilot study.120

Future Perspectives

The application of EPC seems to improve tissue perfusion and function after ischemia. After the initial flurry of early clinical studies, it is time to reconsider its real potential. In order to advance regenerative medicine, deeper knowledge of the underlying mechanism in this treatment is mandatory. The disappointing regional retention of transplanted cells at this time, for example, needs improvement. In the clinical setting, cell type, dosage, and timing of application need further refinement. Even though the clinical application seemed to be safe over a span of months, long-term follow-ups for adverse events, morbidity, mortality, and quality of life are essential before final safety conclusions can be drawn. Overall, conducting large-scale, double-blinded, randomized, controlled studies is the only way to find the answers to remaining questions and ensure patient safety and improved outcomes.

Regardless of detailed mechanisms, we and others truly believe that regenerative cell therapy offers the potential to reestablish perfusion and regain function of injured organs by means of neovascularization and secretion of proangiogenic factors in cardiovascular-renal disease.121–123 Early experiences of clinical applications in the field of renal disease should follow the promising results realized in applying this method for cardiac disease very soon. Depending on further molecular insights, we envision a combination, multistep approach including SC and progenitor cells, multiple, precisely timed factors, and even more to lift regenerative medicine to the next level.

Disclosures

None.

Acknowledgments

This study was supported in part by National Institutes of Health grants HL-53354, HL-57516, HL-77428, HL-63414, HL-80137, and PO1HL-66957. Dr. Jörn Tongers was supported by the German Heart Foundation.

We thank Mickey Neely for administrative support.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2007 American Society of Nephrology

References

  1. ↵
    Gheorghiade M, Bonow RO: Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 97 : 282 –289, 1998
    OpenUrlFREE Full Text
  2. ↵
    Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D: The prevalence of peripheral arterial disease in a defined population. Circulation 71 : 510 –515, 1985
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Golomb BA, Dang TT, Criqui MH: Peripheral arterial disease: Morbidity and mortality implications. Circulation 114 : 688 –699, 2006
    OpenUrlFREE Full Text
  4. ↵
    Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 : 1608 –1621, 2001
    OpenUrlCrossRefPubMed
  5. ↵
    Levey AS: Clinical practice: Nondiabetic kidney disease. N Engl J Med 347 : 1505 –1511, 2002
    OpenUrlCrossRefPubMed
  6. ↵
    Drueke TB: Aspects of cardiovascular burden in pre-dialysis patients. Nephron 85[Suppl 1] : 9 –14, 2000
    OpenUrl
  7. ↵
    Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 : 434 –438, 1999
    OpenUrlCrossRefPubMed
  8. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM, Asahara T: Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 86 : 1198 –1202, 2000
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 : 430 –436, 2001
    OpenUrlCrossRefPubMed
  10. ↵
    Asahara T, Takeshita S, Tsurumi Y, Feldman L, Isner JM: Arterial gene therapy: A molecular biological perspective for the treatment of arterial ischemia. Z Kardiol 86[Suppl 1] : 65 –69, 1997
    OpenUrl
  11. ↵
    Urbich C, Dimmeler S: Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 95 : 343 –353, 2004
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 : 964 –967, 1997
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Pillarisetti K, Gupta SK: Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1): SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation 25 : 293 –300, 2001
    OpenUrlCrossRefPubMed
  14. ↵
    Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 : 858 –864, 2004
    OpenUrlCrossRefPubMed
  15. ↵
    Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362 : 697 –703, 2003
    OpenUrlCrossRefPubMed
  16. ↵
    Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA: Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342 : 626 –633, 2000
    OpenUrlCrossRefPubMed
  17. ↵
    Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 : 221 –228, 1999
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 : 625 –637, 2002
    OpenUrlCrossRefPubMed
  19. ↵
    Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 : 1370 –1376, 2003
    OpenUrlCrossRefPubMed
  20. ↵
    Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76 : 301 –314, 1994
    OpenUrlCrossRefPubMed
  21. ↵
    Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107 : 1322 –1328, 2003
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL: Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 195 : 1145 –1154, 2002
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schachinger V, Dimmeler S, Zeiher AM: Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): Mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 108 : 2212 –2218, 2003
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Landmesser U, Hornig B, Drexler H: Endothelial function: A critical determinant in atherosclerosis? Circulation 109 : II27 –II33, 2004
    OpenUrlCrossRefPubMed
  25. ↵
    Lerman A, Zeiher AM: Endothelial function: Cardiac events. Circulation 111 : 363 –368, 2005
    OpenUrlFREE Full Text
  26. ↵
    Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9 : 702 –712, 2003
    OpenUrlCrossRefPubMed
  27. ↵
    Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for circulating bone marrow-derived endothelial cells. Blood 92 : 362 –367, 1998
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM: Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 : 3017 –3024, 2002
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G: Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 93 : e17 –e24, 2003
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97 : 3422 –3427, 2000
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103 : 634 –637, 2001
    OpenUrlAbstract/FREE Full Text
  32. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S: Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108 : 2511 –2516, 2003
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103 : 2776 –2779, 2001
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Goodell MA, Jackson KA, Majka SM, Mi T, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK: Stem cell plasticity in muscle and bone marrow. Ann N Y Acad Sci 938 : 208 –218; discussion 218–220, 2001
    OpenUrlCrossRefPubMed
  35. ↵
    Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P: Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 938 : 221 –229, discussion 229–230, 2001
    OpenUrlPubMed
  36. ↵
    Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428 : 664 –668, 2004
    OpenUrlCrossRefPubMed
  37. ↵
    Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC: Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428 : 668 –673, 2004
    OpenUrlCrossRefPubMed
  38. ↵
    Hillebrands JL, Klatter FA, van Dijk WD, Rozing J: Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med 8 : 194 –195, 2002
    OpenUrlCrossRefPubMed
  39. ↵
    Wagers AJ, Sherwood RI, Christensen JL, Weissman IL: Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297 : 2256 –2259, 2002
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W: Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94 : 230 –238, 2004
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S, Murohara T, Imaizumi T, Iwasaka T: Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104 : 1046 –1052, 2001
    OpenUrlAbstract/FREE Full Text
  42. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE: Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94 : 678 –685, 2004
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Rehman J, Li J, Orschell CM, March KL: Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 : 1164 –1169, 2003
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133 : 275 –288, 1971
    OpenUrlAbstract
  45. ↵
    Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE: Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109 : 1543 –1549, 2004
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Heil M, Ziegelhoeffer T, Mees B, Schaper W: A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. Circ Res 94 : 573 –574, 2004
    OpenUrlFREE Full Text
  47. ↵
    Losordo DW, Dimmeler S: Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II—Cell-based therapies. Circulation 109 : 2692 –2697, 2004
    OpenUrlFREE Full Text
  48. ↵
    Kalka C, Tehrani H, Laudenberg B, Vale PR, Isner JM, Asahara T, Symes JF: VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 70 : 829 –834, 2000
    OpenUrlCrossRefPubMed
  49. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T: Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105 : 732 –738, 2002
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, Iwasaka T: Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 106 : 2019 –2025, 2002
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18 : 3964 –3972, 1999
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE: Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study. J Am Coll Cardiol 41 : 1721 –1724, 2003
    OpenUrlCrossRefPubMed
  53. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, Imada T, Iwasaka T: Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 22 : 1804 –1810, 2002
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T: Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107 : 461 –468, 2003
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98 : 10344 –10349, 2001
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A: Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 42 : 2073 –2080, 2003
    OpenUrlCrossRefPubMed
  57. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C: Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 45 : 1441 –1448, 2005
    OpenUrlCrossRefPubMed
  58. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, Murohara T: Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24 : 1442 –1447, 2004
    OpenUrlAbstract/FREE Full Text
  59. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106 : 2781 –2786, 2002
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 : 2885 –2890, 2001
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 : 593 –600, 2003
    OpenUrlCrossRefPubMed
  62. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS: Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 109 : 2986 –2992, 2004
    OpenUrlAbstract/FREE Full Text
  63. Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R: Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 24 : 684 –690, 2004
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S: Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109 : 1615 –1622, 2004
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L: Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105 : 199 –206, 2005
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R: CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110 : 1209 –1212, 2004
    OpenUrlAbstract/FREE Full Text
  67. ↵
    George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A, Herz I, Miller H, Keren G: Circulating endothelial progenitor cells in patients with unstable angina: Association with systemic inflammation. Eur Heart J 25 : 1003 –1008, 2004
    OpenUrlCrossRefPubMed
  68. ↵
    Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G: Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109 : 220 –226, 2004
    OpenUrlAbstract/FREE Full Text
  69. ↵
    Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 : 391 –397, 2001
    OpenUrlCrossRefPubMed
  70. ↵
    Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D: Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45 : 526 –529, 2005
    OpenUrlAbstract/FREE Full Text
  71. ↵
    Witzgall R, Brown D, Schwarz C, Bonventre JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney: Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 93 : 2175 –2188, 1994
    OpenUrlCrossRefPubMed
  72. ↵
    Ito T, Suzuki A, Imai E, Okabe M, Hori M: Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 12 : 2625 –2635, 2001
    OpenUrlAbstract/FREE Full Text
  73. ↵
    de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D: Uremia causes endothelial progenitor cell deficiency. Kidney Int 66 : 641 –646, 2004
    OpenUrlCrossRefPubMed
  74. ↵
    Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 : 1246 –1252, 2004
    OpenUrlAbstract/FREE Full Text
  75. ↵
    Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J: Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 44 : 840 –849, 2004
    OpenUrlCrossRefPubMed
  76. ↵
    Soler MJ, Martinez-Estrada OM, Puig-Mari JM, Marco-Feliu D, Oliveras A, Vila J, Mir M, Orfila A, Vilaro S, Lloveras J: Circulating endothelial progenitor cells after kidney transplantation. Am J Transplant 5 : 2154 –2159, 2005
    OpenUrlCrossRefPubMed
  77. ↵
    Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, Takano R, Kusano E, Shimada K, Ikeda U: Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 19 : 627 –633, 2003
    OpenUrlCrossRefPubMed
  78. ↵
    Westerweel PE, Hoefer IE, Blankestijn PJ, de Bree P, Groeneveld DJ, van Oostrom O, Braam B, Koomans HA, Verhaar M: End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 292 : F1132 –F1140, 2007
    OpenUrlCrossRefPubMed
  79. ↵
    de Groot K, Bahlmann FH, Bahlmann E, Menne J, Haller H, Fliser D: Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 79 : 941 –945, 2005
    OpenUrlCrossRefPubMed
  80. ↵
    Herbrig K, Gebler K, Oelschlaegel U, Pistrosch F, Foerster S, Wagner A, Gross P, Passauer J: Kidney transplantation substantially improves endothelial progenitor cell dysfunction in patients with end-stage renal disease. Am J Transplant 6 : 2922 –2928, 2006
    OpenUrlCrossRefPubMed
  81. ↵
    Chan CT, Li SH, Verma S: Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 289 : F679 –F684, 2005
    OpenUrlCrossRefPubMed
  82. ↵
    Haller H, de Groot K, Bahlmann F, Elger M, Fliser D: Stem cells and progenitor cells in renal disease. Kidney Int 68 : 1932 –1936, 2005
    OpenUrlCrossRefPubMed
  83. ↵
    Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 : 1340 –1346, 2003
    OpenUrlAbstract/FREE Full Text
  84. ↵
    Arriero M, Brodsky SV, Gealekman O, Lucas PA, Goligorsky MS: Adult skeletal muscle stem cells differentiate into endothelial lineage and ameliorate renal dysfunction after acute ischemia. Am J Physiol Renal Physiol 287 : F621 –F627, 2004
    OpenUrlCrossRefPubMed
  85. ↵
    Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int 24 : 626 –631, 1983
    OpenUrlCrossRefPubMed
  86. ↵
    Rookmaaker MB, Smits AM, Tolboom H, Van ’t Wout K, Martens AC, Goldschmeding R, Joles JA, Van Zonneveld AJ, Grone HJ, Rabelink TJ, Verhaar MC: Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol 163 : 553 –562, 2003
    OpenUrlCrossRefPubMed
  87. ↵
    Ikarashi K, Li B, Suwa M, Kawamura K, Morioka T, Yao J, Khan F, Uchiyama M, Oite T: Bone marrow cells contribute to regeneration of damaged glomerular endothelial cells. Kidney Int 67 : 1925 –1933, 2005
    OpenUrlCrossRefPubMed
  88. ↵
    Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, van Es LA, Bruijn JA, van Krieken JH: Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 357 : 33 –37, 2001
    OpenUrlCrossRefPubMed
  89. ↵
    Uchimura H, Marumo T, Takase O, Kawachi H, Shimizu F, Hayashi M, Saruta T, Hishikawa K, Fujita T: Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol 16 : 997 –1004, 2005
    OpenUrlAbstract/FREE Full Text
  90. ↵
    Imasawa T, Utsunomiya Y, Kawamura T, Zhong Y, Nagasawa R, Okabe M, Maruyama N, Hosoya T, Ohno T: The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 12 : 1401 –1409, 2001
    OpenUrlAbstract/FREE Full Text
  91. ↵
    Masuya M, Drake CJ, Fleming PA, Reilly CM, Zeng H, Hill WD, Martin-Studdard A, Hess DC, Ogawa M: Hematopoietic origin of glomerular mesangial cells. Blood 101 : 2215 –2218, 2003
    OpenUrlAbstract/FREE Full Text
  92. ↵
    Kale S, Karihaloo A, Clark PR, Kashgarian M, Krause DS, Cantley LG: Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 112 : 42 –49, 2003
    OpenUrlCrossRefPubMed
  93. ↵
    Gupta S, Verfaillie C, Chmielewski D, Kim Y, Rosenberg ME: A role for extrarenal cells in the regeneration following acute renal failure. Kidney Int 62 : 1285 –1290, 2002
    OpenUrlCrossRefPubMed
  94. ↵
    Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 : 1913 –1918, 2002
    OpenUrlAbstract/FREE Full Text
  95. ↵
    Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 53 : 31 –47, 2002
    OpenUrlCrossRefPubMed
  96. ↵
    Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J: Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 108 : 863 –868, 2003
    OpenUrlAbstract/FREE Full Text
  97. ↵
    Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, Eckey T, Henze E, Zeiher AM, Dimmeler S: Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107 : 2134 –2139, 2003
    OpenUrlAbstract/FREE Full Text
  98. ↵
    Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111 : 2198 –2202, 2005
    OpenUrlAbstract/FREE Full Text
  99. ↵
    Ohtsuka M, Takano H, Zou Y, Toko H, Akazawa H, Qin Y, Suzuki M, Hasegawa H, Nakaya H, Komuro I: Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18 : 851 –853, 2004
    OpenUrlCrossRefPubMed
  100. ↵
    Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM: Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106 : 3009 –3017, 2002
    OpenUrlAbstract/FREE Full Text
  101. ↵
    Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de la Fuente L, Gomez-Bueno M, Cantalapiedra A, Fernandez J, Gutierrez O, Sanchez PL, Hernandez C, Sanz R, Garcia-Sancho J, Sanchez A: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 95 : 742 –748, 2004
    OpenUrlAbstract/FREE Full Text
  102. ↵
    Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44 : 1690 –1699, 2004
    OpenUrlCrossRefPubMed
  103. ↵
    Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 364 : 141 –148, 2004
    OpenUrlCrossRefPubMed
  104. ↵
    Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367 : 113 –121, 2006
    OpenUrlCrossRefPubMed
  105. ↵
    Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355 : 1199 –1209, 2006
    OpenUrlCrossRefPubMed
  106. ↵
    Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 : 1210 –1221, 2006
    OpenUrlCrossRefPubMed
  107. ↵
    Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H: Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113 : 1287 –1294, 2006
    OpenUrlAbstract/FREE Full Text
  108. ↵
    Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, Oh BH, Lee MM, Park YB: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 363 : 751 –756, 2004
    OpenUrlCrossRefPubMed
  109. ↵
    Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA: Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 112 : I73 –80, 2005
    OpenUrlCrossRefPubMed
  110. ↵
    Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco G, Bugli AM, Della Porta M, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi G, Ferrari R: Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile. Eur Heart J 26 : 1838 –1845, 2005
    OpenUrlCrossRefPubMed
  111. ↵
    Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, Esato K: Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: Clinical trial and preliminary results. Jpn Circ J 65 : 845 –847, 2001
    OpenUrlCrossRefPubMed
  112. ↵
    Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 : 2294 –2302, 2003
    OpenUrlAbstract/FREE Full Text
  113. ↵
    Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361 : 47 –49, 2003
    OpenUrlCrossRefPubMed
  114. ↵
    Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO 3rd: Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46 : 1643 –1648, 2005
    OpenUrlCrossRefPubMed
  115. ↵
    Stamm C, Kleine HD, Westphal B, Petzsch M, Kittner C, Nienaber CA, Freund M, Steinhoff G: CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg 52 : 152 –158, 2004
    OpenUrlCrossRefPubMed
  116. ↵
    Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361 : 45 –46, 2003
    OpenUrlCrossRefPubMed
  117. ↵
    Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kogler G, Wernet P, Muller HW, Kostering M: Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: The IACT Study. J Am Coll Cardiol 46 : 1651 –1658, 2005
    OpenUrlCrossRefPubMed
  118. ↵
    Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 : 1222 –1232, 2006
    OpenUrlCrossRefPubMed
  119. ↵
    Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360 : 427 –435, 2002
    OpenUrlCrossRefPubMed
  120. ↵
    Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D: Erythropoietin regulates endothelial progenitor cells. Blood 103 : 921 –926, 2004
    OpenUrlAbstract/FREE Full Text
  121. ↵
    Dimmeler S, Zeiher AM, Schneider MD: Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 115 : 572 –583, 2005
    OpenUrlCrossRefPubMed
  122. Losordo DW, Dimmeler S: Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part I—Angiogenic cytokines. Circulation 109 : 2487 –2491, 2004
    OpenUrlFREE Full Text
  123. ↵
    Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG: Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 46 : 7 –18, 2005
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 18 (11)
Journal of the American Society of Nephrology
Vol. 18, Issue 11
November 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Frontiers in Nephrology: The Evolving Therapeutic Applications of Endothelial Progenitor Cells
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Frontiers in Nephrology: The Evolving Therapeutic Applications of Endothelial Progenitor Cells
Jörn Tongers, Douglas W. Losordo
JASN Nov 2007, 18 (11) 2843-2852; DOI: 10.1681/ASN.2007050597

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Frontiers in Nephrology: The Evolving Therapeutic Applications of Endothelial Progenitor Cells
Jörn Tongers, Douglas W. Losordo
JASN Nov 2007, 18 (11) 2843-2852; DOI: 10.1681/ASN.2007050597
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • EPC
    • Clinical Implications of EPC
    • Therapeutic Applications
    • Future Perspectives
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • Ensuring the Equitable Advancement of American Kidney Health—the Need to Account for Socioeconomic Disparities in the ESRD Treatment Choices Model
  • New ‘Antigens’ in Membranous Nephropathy
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more UP FRONT MATTERS

Special Articles

  • Cellular and Molecular Mechanisms of AKI
  • Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN
  • Renal Hemodynamics in AKI: In Search of New Treatment Targets
Show more Special Articles

Cited By...

  • Autonomic-Immune-Vascular Interaction: An Emerging Concept for Neurogenic Hypertension
  • Angiomyeloproliferative Lesions Following Autologous Stem Cell Therapy
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire